NSABP B-31

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。该研究的主要目的是：1)比较可手术、组织学上淋巴结阳性且HER2蛋白过表达的乳腺癌患者，4个周期AC + 4个周期紫杉醇与相同化疗方案加赫赛汀的心脏毒性；2)确定在该患者群体中，4个周期AC + 4个周期紫杉醇+每周赫赛汀治疗1年是否比4个周期AC + 4个周期紫杉醇更有效地延长生存期

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of AC followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in prolonging survival than four cycles of AC followed by four cycles of Taxol